Union Therapeutics on new Covid-19 deal: Treatments can be easier and cheaper
A new options agreement with US company TFF Pharmaceuticals gives Union Therapeutics access to a potentially cheaper version of the drug Niclosamide, which the firm is already developing as treatment against Covid-19.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Union Therapeutics has not been involved in the development of Covid-19 treatments for many months, but nonetheless, the company is pacing forward at full speed and currently taking one of its drugs through phase I.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
